Literature DB >> 16289617

Differential sensitivity of liposarcoma subtypes to chemotherapy.

Robin L Jones1, Cyril Fisher, Omar Al-Muderis, Ian R Judson.   

Abstract

Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic. However, the response of these subgroups to chemotherapy is not well documented. In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital. Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified. The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated. Survival according to histological grade was also assessed. A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28-69) and 11% (95%CI; 2-29), P = 0.005. Similarly, those with myxoid liposarcoma had a significantly higher response rate compared to all other liposarcoma patients, 48% (95%CI; 28-69) and 18% (95%CI; 8-31). Patients with lower grade tumours had better overall survival. This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours. Further confirmation of these results should be sought by similar analyses of other databases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289617     DOI: 10.1016/j.ejca.2005.07.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  102 in total

1.  Aberrant AKT activation drives well-differentiated liposarcoma.

Authors:  Alejandro Gutierrez; Eric L Snyder; Adrian Marino-Enriquez; Yi-Xiang Zhang; Stefano Sioletic; Elena Kozakewich; Ruta Grebliunaite; Wen-Bin Ou; Ewa Sicinska; Chandrajit P Raut; George D Demetri; Antonio R Perez-Atayde; Andrew J Wagner; Jonathan A Fletcher; Christopher D M Fletcher; A Thomas Look
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Primary liposarcoma of the ascending colon: a rare case of mixed type presenting as hemoperitoneum combined with other type of retroperitoneal liposarcoma.

Authors:  Yoon Young Choi; Yong Jin Kim; So Young Jin
Journal:  BMC Cancer       Date:  2010-05-27       Impact factor: 4.430

3.  Phase I study of nelfinavir in liposarcoma.

Authors:  Janet Pan; Michelle Mott; Bixin Xi; Ernestine Hepner; Min Guan; Kristen Fousek; Rachel Magnusson; Raechelle Tinsley; Frances Valdes; Paul Frankel; Timothy Synold; Warren A Chow
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-16       Impact factor: 3.333

4.  Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.

Authors:  Takeaki Ishii; Kenichi Kohashi; Kunio Iura; Akira Maekawa; Hirofumi Bekki; Yuichi Yamada; Hidetaka Yamamoto; Kazuki Nabeshima; Hiroyuki Kawashima; Yukihide Iwamoto; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-10-30

5.  Laryngeal dedifferentiated liposarcoma.

Authors:  Marc Makeieff; Pierfrancesco Pelliccia; Flora Poizat; Sebastien Arnaud; Florien Rat; Didier Cupissol; Bernard Guerrier; Valérie Costes
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04-10       Impact factor: 2.503

6.  The MDM2 inducible promoter folds into four-tetrad antiparallel G-quadruplexes targetable to fight malignant liposarcoma.

Authors:  Sara Lago; Matteo Nadai; Emanuela Ruggiero; Martina Tassinari; Maja Marušič; Beatrice Tosoni; Ilaria Frasson; Filippo M Cernilogar; Valentina Pirota; Filippo Doria; Janez Plavec; Gunnar Schotta; Sara N Richter
Journal:  Nucleic Acids Res       Date:  2021-01-25       Impact factor: 16.971

Review 7.  Lipomatous tumours of the head and neck: a spectrum of biological behaviour.

Authors:  Eelco de Bree; Alexander Karatzanis; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Robert P Takes; Alfio Ferlito; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-07       Impact factor: 2.503

8.  Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.

Authors:  Ronald S A de Vreeze; Daphne de Jong; Petra M Nederlof; Aafke Ariaens; Ivon H G Tielen; Luc Frenken; Rick L Haas; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

9.  Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.

Authors:  Anna Minchom; Robin L Jones; Cyril Fisher; Omar Al-Muderis; Sue Ashley; Michelle Scurr; Vasilios Karavasilis; Ian R Judson
Journal:  Sarcoma       Date:  2010-05-20

10.  Guidelines for the management of soft tissue sarcomas.

Authors:  Robert Grimer; Ian Judson; David Peake; Beatrice Seddon
Journal:  Sarcoma       Date:  2010-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.